EMA Backs Two New Options for NSCLC
Summary
The CHMP has backed Zybrivo plus chemotherapy for first-line nonsquamous NSCLC and Aumseqa for advanced EGFR-mutated disease. Medscape News Europe
Description from Medscape.
Who is covering this
-
EMA Backs Two New Options for NSCLC
The CHMP has backed Zybrivo plus chemotherapy for first-line nonsquamous NSCLC and Aumseqa for advanced EGFR-mutated disease. Medscape News Europe
Comments
Comments need JavaScript.